Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2
Release Date:
Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.Read the full article:Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2